July/August 2005, Volume 11, Issue 6

Direct Costs of Opioid Abuse in an Insured Population in the United States

ALAN G. WHITE, PhD; HOWARD G. BIRNBAUM, PhD; MILENA N. MAREVA, BA; MAHAM DAHER, BA; SUSAN VALLOW, RPh, MBA, MA; JEFF SCHEIN, DrPH, MPH; and NATHANIEL KATZ, MD

ABSTRACT

OBJECTIVE: To (a) describe the demographics of opioid abusers; (b) compare the prevalence rates of selected comorbidities and the medical and drug utilization patterns of opioid abusers with patients from a control group, for the period from 1998 to 2002; and (c) calculate the mean annual per-patient total health care costs (e.g., inpatient, outpatient, emergency room, drug, other) from the perspective of a private payer.

METHODS: An administrative database of medical and pharmacy claims from 1998 to 2002 of 16 self-insured employer health plans with approximately 2 million lives was used to identify "opioid abusers"—patients with claims associated with ICD-9-CM (*International Classification of Diseases, 9th Revision, Clinical Modification*) codes for opioid abuse (304.0, 304.7, 305.5, and 965.0 [excluding 965.01]). A control group of nonabusers was selected using a matched sample (by age, gender, employment status, and census region) in a 3:1 ratio. Per-patient annual health care costs (mean total medical and drug costs) were measured in 2003 U.S. dollars. Multivariate regression techniques were also used to control for comorbidities and to compare costs with a benchmark of depressed patients.

RESULTS: 740 patients were identified as opioid abusers, a prevalence of 8 in 10,000 persons aged 12 to 64 years continuously enrolled in health care plans for whom 12 months of data were available for calculating costs. Opioid abusers, compared with nonabusers, had significantly higher prevalence rates for a number of specific comorbidities, including nonopioid poisoning, hepatitis (A, B, or C), psychiatric illnesses, and pancreatitis, which were approximately 78, 36, 9, and 21 ($P < 0.01$) times higher, respectively, compared with nonabusers. Opioid abusers also had higher levels of medical and prescription drug utilization. Almost 60% of opioid abusers had prescription drug claims for opioids compared with approximately 20% for nonabusers. Prevalence rates for hospital inpatient visits for opioid abusers were more than 12 times higher compared with nonabusers ($P < 0.01$).

Mean annual direct health care costs for opioid abusers were more than 8 times higher than for nonabusers (\$15,884 versus \$1,830, respectively, $P < 0.01$). Hospital inpatient and physician-outpatient costs accounted for 46% (\$7,239) and 31% (\$5,000) of opioid abusers' health care costs, compared with 17% (\$310) and 50% (\$906), respectively, for nonabusers. Mean drug costs for opioid abusers were more than 5 times higher than costs for nonabusers (\$2,034 vs. \$386, respectively, $P < 0.01$), driven by higher drug utilization (including opioids) for opioid abusers. Even when controlling for comorbidities using a multivariate regression model of a matched control of depressed patients, the average health care costs of opioid abusers were 1.8 times higher than the average health care costs of depressed patients.

CONCLUSION: The high costs of opioid abuse were driven primarily by high prevalence rates of costly comorbidities and high utilization rates of medical services and prescription drugs.

KEYWORDS: Opioid abuse, Prevalence rates, Direct health care costs

Opioid abuse can impose substantial costs on society and to payers as well as to the users themselves. Although there has been some research on the overall costs of opioid abuse, few studies have undertaken systematic research of costs from the payer perspective and quantified the payer burden of opioid abuse. In this article, we analyzed the economic burden of opioid abuse (both prescription and non-prescription) from a private payer's perspective. The analysis focused on average per-patient direct health care costs (medical and drug) measured in 2003 United States dollars.

A number of studies have discussed the growing prevalence of opioid abuse in the United States. The National Household Survey on Drug Abuse (NHSDA) estimated that more than 6 million Americans used prescription pain relievers (e.g., oxycodone) for nonmedical purposes in 1999. By 2001, this number had increased to 8.4 million, approximately 4 % of the U.S. population.¹⁻³ Findings from the National Survey on Drug Use and Health showed that nonmedical use of pain relievers among persons aged 12 years and older increased from 11.0 million to 11.7 million.⁴ Although these results are not directly comparable with those of the NHSDA, they indicate the growing prevalence of opioid abuse in the United States.

From 1999 to 2001, the number of patients admitted for the treatment of prescription opioid abuse increased from approximately 23,000 in 1999 to more than 38,000 in 2001.⁵ Furthermore, the number of emergency room visits related to illegal drug use or nonmedical use of prescription drugs increased from approximately 250,000 in the latter half of 1997 to more than 325,000 in the latter half of 2001.⁶ The growing prevalence of drug and opioid abuse has caused an increase in

government attention devoted to this problem; in 2001, the National Institute of Drug Abuse launched a public information campaign to educate patients, health care providers, and pharmacists regarding the potential dangers of prescription drug abuse.⁷

Several researchers have attempted to quantify the costs associated with drug abuse, including opioid abuse. Without distinguishing between legal and illegal drug use, Harwood estimated that overall costs of drug abuse in 1998 were \$97.7 billion.⁸ His study focused on 3 major cost categories: health care, criminal justice, and workplace burden costs. The National Institutes of Health reported that, in 1998, the overall cost of drug abuse was \$143.4 billion, with 69% in lost productivity costs, 9% in health costs, and 22% in other costs such as criminal justice.⁹ There have also been a few studies that have focused on the costs associated with illicit drug abuse.^{10,11}

Only one study was found that focused on prescription opioid abuse in particular. Birnbaum et al. found that the cost of prescription opioid abuse in the United States in 2001 was \$9.2 billion; approximately 30% (\$2.8 billion) was for health care, 50% (\$4.6 billion) for lost productivity, and 20% (\$1.8 billion) for criminal justice.¹² Given the trends in increasing prevalence rates of prescription opioid abuse, its economic burden on society is very likely to escalate in the coming years. Furthermore, since the condition is likely to be underdiagnosed because of the associated stigma, the true burden is probably much greater.

This article focuses on the payer burden of opioid abuse by measuring the per-patient costs incurred by payers arising from all medical and pharmacy payments made for patients diagnosed with opioid abuse (i.e., related to opioid abuse and other comorbid conditions).

Methods

Overview

A group of patients with a diagnosis of opioid abuse was identified and randomly matched to a group of patients with no diagnoses of opioid abuse. Medical and pharmacy claims and eligibility data were used to compare the demographic characteristics, medical services and drug utilization, prevalence rates of selected comorbidities, and average annual direct health care (i.e., medical and drug) costs for patients for both groups. Patient samples were identified using ICD-9-CM (*International Classification of Diseases, 9th Revision, Clinical Modification*) codes for opioid abuse. The difference in costs between these 2 groups was used to calculate the excess burden of opioid abuse (i.e., the extent to which health care costs of opioid abusers were greater than those of nonabusers). Costs were measured as payer payments for services provided during a 12-month period for each patient during the years 1998-2002, and were adjusted to 2003 U.S. dollars using the medical consumer price subindex. Descriptive statistics for medical services and drug utilization, prevalence

rates of selected comorbidities, and direct health care costs were compared for opioid abusers and nonabusers.

Data

The database contained deidentified administrative claims data for approximately 2 million insured members from 16 large employers for the period from 1998-2002. Together these employers had operations nationwide in a broad array of industries and job classifications. The data included all medical (e.g., hospital inpatient, physician office visits, etc.) as well as prescription drug claims for employees, spouses, and dependents. Prescription drug utilization was identified using both National Drug Codes (NDCs) for drug claims and Health Care Financing Administration Common Procedure Coding System (HCPCS) codes for medical claims where drugs were administered as part of a medical procedure. The data allowed for disaggregation of costs by place of service (e.g., hospital outpatient versus hospital inpatient). The data could therefore be used to compare the drivers of total payer costs across opioid abusers and nonabusers. The data also allowed comparison of medical and drug utilization and prevalence rates of selected pre-specified comorbidities across opioid abusers and nonabusers. The prevalence rates were compared by calculating relative risk ratios (i.e., the ratio of the respective prevalence rates for opioid abusers to nonabusers), and statistical differences in prevalence rates were assessed using a chi-squared analysis. Differences in averages between the 2 samples were assessed using *t* tests.

Identification of Research Samples

The patient research samples were identified as patients between the ages of 12 and 64 years who were continuously enrolled in health care plans for a 12-month period around the index date (defined below). Patients were identified as opioid abusers based on having at least 1 claim with at least 1 of the following 4 ICD-9-CM codes over the period 1998-2002:

- 304.0 opioid type dependence
- 304.7 combinations of opioid abuse with any other
- 305.5 opioid abuse
- 965.0 poisoning by opiates and related narcotics excluding poisoning by heroin (965.01)

The index date in this study was defined as the first observed date of diagnosis of opioid abuse. Patients were included if they had claims history for at least 6 months preindex date and 6 months postindex date. The index date was not necessarily the first date of diagnosis of opioid abuse, given the requirement of 6 months of medical claims history prior to the index date. If a patient was diagnosed with opioid abuse in February 1998, then this patient would not be included in the analysis, given that the patient would not have had at least 6 months of preindex date medical claims history (assuming there were no subsequent claims associated with opioid abuse). Patients were required to be continuously enrolled in health

care plans during all 12 months of the study (i.e., the 6 months preindex and postindex date). The sample is likely to contain both prescription opioid abusers and nonprescription opioid abusers, since ICD-9-CM codes do not distinguish between the 2 types of opioid abuse.

It is worth noting that the term “opioid abuse” is a general term, used differently by different people in various contexts. In some cases, it means a less serious form of addiction, i.e., someone appears to be addicted but doesn’t meet the full *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) criteria for addiction (opioid dependence).⁷ In fact DSM-IV has specific criteria for opioid abuse. Definitions of prescription opioid abuse span a spectrum from episodic nonmedical use of a drug (Drug Enforcement Agency and National Institute for Drug Abuse) to nonmedical use resulting in harm (Institute of Medicine and Drug Abuse Warning Network) to very specific criteria such as those in DSM-IV.⁷ In 2001, The American Academy of Pain Medicine issued recommendations for distinguishing between “physical dependence” and “addiction,” where *physical dependence* referred to a condition characterized by withdrawal symptoms when one stops using opioids. By contrast, *addiction* “is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.”¹³

Given the different uses of the term opioid abuse and the possibility for miscoding with the ICD-9-CM codes, we grouped all such ICD-9-CM codes that related to opioid abuse for the purposes of our cost calculations and analyses and labeled these patients “opioid abusers.” However, recognizing that abuse and dependence may not necessarily be synonymous, we report some sensitivity analyses based on different cohorts defined by ICD-9-CM codes. These are discussed below.

A random sample was also drawn from the same overall patient population to serve as a comparison group. The same basic inclusion criteria imposed on the opioid abuse sample were also imposed on the matched sample: aged 12 to 64 years, continuously enrolled in a health care plan during all 12 months of the study period, and having at least 1 medical or prescription drug claim during that year. The random sample excluded patients with opioid abuse diagnoses and was matched with the opioid abuse sample by gender, age, employment status, and census geographic region on a 3:1 matching ratio.

An important feature of the analysis is that there was no “wash-out” period before or after claims associated with the ICD-9-CM codes for the opioid abusers in the study. Studies that impose a wash-out period before the first diagnosis and after the end of a “disease episode” are generally focused on capturing the cost of illness associated with the onset of the disease in question and its immediate treatment. In contrast, the goal of the current study was to capture a payer’s typical direct medical cost burden for the average annual cost of illness for all patients diagnosed with opioid abuse who may have been in

TABLE 1 Demographic Profile of Opioid Abusers and Nonabusers, 1998-2002 (Patients Aged 12-64 Years)

	Opioid Abusers* (N = 740)		Nonabusers* (N = 2,220)	
	N	%	N	%
Gender				
Male	422	57.0	1,266	57.0
Female	318	43.0	954	43.0
Age (years)				
Mean	37.6		37.4	
Median	39.0		39.0	
Standard deviation	13.3		13.5	
12-17	56	7.6	168	7.6
18-34	222	30.0	666	30.0
35-54	389	52.6	1,167	52.6
55-64	73	9.9	219	9.9
Region				
Midwest	105	14.2	315	14.2
Northeast	153	20.7	459	20.7
South	388	52.4	1,164	52.4
West	94	12.7	282	12.7

* Patients are required to have medical claims data 6 months preindex date and 6 months postindex date during which they are continuously enrolled in a health care plan. The index date here is defined as the first date for a claim associated with an opioid abuse ICD-9-CM code that satisfies the above enrollment requirements.

TABLE 2 Comparison of Prevalence Rates of Selected Comorbidities 1998-2002 (Patients Aged 12-64 Years)

Comorbidities†	Opioid Abusers (N = 740)		Nonabusers (N = 2,220)		Relative Risk Ratio [E] = [B]/[D]	P Value*
	N	%	N	%		
	[A]	[B]	[C]	[D]		
Nonopioid poisoning	130	17.6	5	0.2	78.0	<0.01
Hepatitis (A,B, and C)	48	6.5	4	0.2	36.0	<0.01
Other substance abuse	373	50.4	26	1.2	43.0	<0.01
Pancreatitis	7	0.9	1	0.05	21.0	<0.01
Psychiatric diagnoses	526	71.1	186	8.4	8.5	<0.01
Cirrhosis/chronic or acute liver disease	33	4.5	13	0.6	7.6	<0.01
Motor vehicle traffic accidents	10	1.4	5	0.2	6.0	<0.01
HIV/AIDS	10	1.4	6	0.3	5.0	<0.01
Hepatitis (E and Other)	3	0.4	2	0.1	4.5	0.07
Skin infections/abscesses	75	10.1	55	2.5	4.1	<0.01
Burns	6	0.8	6	0.3	3.0	0.05
Gastrointestinal bleeding	59	8.0	57	2.6	3.1	<0.01
Trauma	270	36.5	333	15.0	2.4	<0.01
Herpes simplex	10	1.4	14	0.6	2.1	0.06
Sexually transmitted diseases	59	8.0	96	4.3	1.8	<0.01
Hepatitis (alcoholic)	1	0.1	0	0.0	—	—
Endocarditis	5	0.7	0	0.0	—	—

* Chi-square tests were conducted to compare the prevalence rates of comorbidities for opioid abusers and nonabusers.

† For ICD-9-CM codes corresponding to each comorbidity group, see Appendix A.

FIGURE 1 Comparison of Medical Utilization Patterns,*† 1998-2002 (Patients Aged 12-64 Years)

* The difference in prevalence rates between abusers and nonabusers for all visit or claim types was found to be statistically significant at the 1% level ($P < 0.01$).

† "N" denotes the number of opioid abusers/nonabusers who had at least 1 visit or claim for the corresponding medical service category. The total number of opioid abusers and nonabusers were 740 and 2,220, respectively.

different stages of their abuse: onset, treatment, management, and/or recovery. In addition, the nature of opioid abuse and the fact that it likely lasts for several years with associated higher prevalence rates of certain comorbidities creates difficulties in identifying the beginning or end of abuse and the costs associated with it. Therefore, by taking a more general cross-sectional approach in calculating the average direct health care costs associated with opioid abuse, patients with varying degrees of severity and in different stages of their illnesses were captured. Thus, we selected patients on the basis of a claim for opioid abuse, conditioned on having their medical claims history for the 6 months preindex and postindex date.

Calculation of Direct Costs

Direct health care costs were calculated based on payments made by payers for inpatient, outpatient, physician, and prescription drug claims as well as for all other medical services. Since the focus of this study was on the payer burden of opioid abuse, these payments did not include deductibles or copay-

ments paid by the patients (i.e., the claim field used in the current study was net plan cost after subtraction of copayments and other member cost share). The dollar amounts for all claims for each patient during the 12 months including the 6-month preindex and 6-month postindex date were summed to arrive at their total direct medical costs. These costs were then averaged over all patients in the research samples to arrive at the average cost per patient for opioid abusers and nonabusers.

Results

The resulting sample sizes for the study were 740 opioid abusers and 2,220 nonabusers. Males accounted for 57% of opioid abusers and nonabusers (Table 1). The average age of opioid abusers was 37.6 years, and 52.6% of opioid abusers were in the 35 to 54-year age range.

The prevalence of opioid abuse among the members in our database increased from 5 per 10,000 in 1998 to 8 per 10,000 in 2002, where the denominator was the total annual number of insured members in each year, and the numerator was the

cumulative number of patients with claims associated with ICD-9-CM codes for opioid abuse in the year. This represents a 60% increase.

The prevalence rates of a number of comorbid conditions between opioid abusers and nonabusers were identified (Table 2). A patient was classified as having a given comorbid condition if the patient had at least 1 claim associated with the ICD-9-CM codes for the conditions over the period 1998-2002 (see Appendix A for the ICD-9-CM codes associated with the comorbid conditions). Among opioid abusers, comorbid conditions such as nonopioid poisoning, hepatitis (A, B, C), psychiatric illnesses, and pancreatitis were 78.0, 36.0, 8.5, and 21.0 ($P < 0.01$) times, respectively, as prevalent as those for nonabusers. Similarly, an analysis of painful comorbidities found that almost half of all opioid abusers had any chronic pain comorbidity (47.6%), with low-back pain being the most prevalent (19.3%, Table 3). The higher prevalence rates of these potentially costly comorbidities likely contributed to the higher health care costs for opioid abusers compared with nonabusers.

Opioid abusers had higher utilization rates of various medical services as measured by the number of claims for medical services (Figure 1). For example, opioid abusers were 11.2 times more likely to have had at least 1 mental health outpatient visit and 12.2 times more likely to have had at least 1 hospital inpatient stay than nonabusers ($P < 0.01$). Furthermore, opioid abusers averaged 18.7 physician or outpatient visits compared with 7 for nonabusers ($P < 0.01$). Opioid abusers were also 4 times more likely to have had an emergency room visit than nonabusers ($P < 0.01$). The high rates of use of medical services by opioid abusers, in combination with their comorbidity profile, likely contributed to their higher average health care costs.

Opioid abusers had higher utilization rates of prescription drugs (Table 4). When one considers all prescription drug use (including opioids and nonopioids), 86.9% of opioid abusers had at least 1 prescription drug claim compared with 61.7% for nonabusers, and opioid abusers had, on average, 41.6 prescription drug claims compared with 13.8 for nonabusers ($P < 0.01$). These drugs were identified using NDCs for drug claims and HCPCS codes for medical claims in the cases of drugs administered as medical procedures. About 58% of opioid abusers had claims for short-acting opioids (SAOs), long-acting opioids (LAOs), or both, compared with about 20% of nonabusers. More than 40% of opioid abusers had claims for SAOs, and about 17% had claims for both SAOs and LAOs. As noted above, almost 50% of opioid abusers had a diagnosis of a chronically painful condition (Table 3), similar to prevalence rates of chronic pain among opioid abusers in another study.¹⁴ This suggests that the rates of opioid claims among opioid abusers coincide with high prevalence rates of chronically painful conditions, noting that the notion of opioid abuse is not always well defined.

TABLE 3 Prevalence Rates of Chronic Painful Comorbidities,* 1998-2002 (Patients Aged 12-64 Years)

	Opioid Abusers (N = 740)		Nonabusers (N = 2,220)		Relative Risk Ratio	P Value†
	N	%	N	%		
Painful Comorbidity	[A]	[B]	[C]	[D]	[E] = [B]/[D]	
Headache/migraine	57	7.7	22	1.0	7.8	<0.01
Other musculoskeletal pain	44	5.9	23	1.0	5.7	<0.01
Low-back pain	143	19.3	79	3.6	5.4	<0.01
Neuropathic pain	18	2.4	10	0.5	5.4	<0.01
Other chronic pain	128	17.3	102	4.6	3.8	<0.01
Arthritis	111	15.0	99	4.5	3.4	<0.01
Other back and neck pain	32	4.3	38	1.7	2.5	<0.01
Cancer	11	1.5	17	0.8	1.9	0.08
Any painful comorbidity‡	352	47.6	384	17.3	2.8	<0.01

* A claimant is considered to have a chronic painful comorbidity if the claimant has at least 2 claims at least 90 days apart within a comorbidity group.

† Chi-square tests were conducted to compare the prevalence rates of comorbidities for the opioid abusers and nonabusers.

‡ "Any painful comorbidity" includes ICD-9-CM codes from any of the painful comorbidity groups: headache/migraine, other musculoskeletal pain, low-back pain, neuropathic pain, other chronic pain, arthritis, other back and neck pain or cancer.

Calculations of the average health care costs for opioid abusers and nonabusers showed that patients who were opioid abusers had health care costs that were more than 8 times higher than those of nonabusers (Figure 2). The total average per-patient direct health care payer cost for opioid abusers was \$15,884 compared with \$1,830 for nonabusers ($P < 0.01$). Statistically significant differences from the matched sample of nonabusers are noted in Figure 2, where applicable. These average per-patient costs included both opioid-abuse related costs (such as substance abuse treatment) in addition to other comorbidity-related costs (such as pancreatitis, hepatitis, etc.) The excess annual cost burden of opioid abuse (i.e., the difference between the average per-patient payer costs of opioid abusers and nonabusers) was \$14,054 per patient.

Disaggregated direct health care costs were also calculated (Appendix B provides a detailed breakdown of costs, by cost component, for both patient samples). Statistically significant differences in average costs between the 2 groups are noted, where applicable. For direct health care costs, hospital inpatient costs accounted for the largest percentage of costs for opioid abusers, 46% compared with 17% for nonabusers (or \$7,239 vs. \$310, $P < 0.01$, or more than 20 times higher). Physician and outpatient visits accounted for 31% of opioid abusers' costs compared with 50% for nonabusers. Although such visits comprised a greater percentage of the costs for nonabusers, the costs

TABLE 4 Comparison of Drug Utilization Patterns, 1998-2002 (Patients Aged 12-64 Years)

	Opioid Abusers (N = 740)					Nonabusers (N = 2,220)					Relative Risk Ratio†	
	Number (%) of Patients With at Least 1 Claim		Number of Claims per Patient			Number (%) of Patients With at Least 1 Claim		Number of Claims per Patient				
			Mean*	SD	Median			Mean*	SD	Median		
		[A]					[B]					[C] = [A]/[B]
Prescription drugs												
All prescription drugs	643	86.9%	41.6 ^a	41.9	27.0	1,369	61.7%	13.8 ^a	19.3	7.0	1.4 ^a	
All nonopioids	637	86.1%	32.4 ^a	32.7	23.0	1,353	60.9%	13.0 ^a	17.5	7.0	1.4 ^a	
Prescription opioids												
SAOs‡ only	304	41.1%	9.4 ^a	11.9	4.0	421	19.0%	2.3 ^a	3.6	1.0	2.2 ^a	
LAOs§ only	7	0.9%	6.9	5.6	9.0	3	0.1%	11.3	14.6	5.0	7.0 ^a	
Both SAOs and LAOs	127	17.2%	25.7	15.5	24.0	8	0.4%	32.1	32.4	23.0	47.6 ^a	

* t tests were conducted to compare the mean number of claims per patient between opioid abusers and nonabusers; ^a denotes significance at the 1% level ($P < 0.01$).

† Chi-square tests were conducted to compare the prevalence rates of drug claims between opioid abusers and nonabusers; ^a denotes significance at the 1% level ($P < 0.01$).

‡ Short-acting (prescription) opioids (SAOs): any prescription drug with these active ingredients: hydrocodone (308 patients), oxycodone (153), tramadol (88), codeine (110), propoxyphene (93), and other SAOs (78, meperidine, butorphanol, fentanyl, hydromorphone, buprenorphine, morphine, pentazocine, dihydrocodeine, opium, sufentanil, nalbuphine or drugs administered as a medical procedure with the following HCPCS codes: J0592, J0745, J1170, S0092, J2175, J2180, J2270, J2271, J2300, and J3010). "SAOs only" includes patients with claims only for SAOs.

§ Long-acting (prescription) opioids (LAOs): oxycodone ER (97 patients), fentanyl transdermal system (38), methadone (29), extended-release morphine (16, including the claims for brand names Kadian, Avinza, MS Contin, Oramorph, Astramorph PF, Duramorph, and Infumorph or extended-release morphine administered as a medical procedure with the following HCPCS codes: J2275 and S0093). "LAOs only" includes patients with claims only for LAOs.

of such visits for opioid abusers were more than 5 times higher compared with nonabusers (\$5,000 vs. \$906, $P < 0.01$). Average drug costs for opioid abusers were more than 5 times higher compared with those for nonabusers (\$2,034 vs. \$386), while such drug costs accounted for 21% of overall costs for nonabusers compared with 13% for opioid abusers.

We also conducted sensitivity analyses on direct health care costs based on different groupings of the ICD-9-CM codes. In particular we divided our sample into 2 subgroups: one based on ICD-9-CM codes 304.7 and 305.5, codes for "abuse" ("Group A," $N = 141$), and another based on the ICD-9-CM codes 304.0 and 965.0, codes for "dependence" and "poisoning" (excluding 965.01, "Group B," $N = 635$). The subgroups are not mutually exclusive since it is possible for a patient to be diagnosed with more than one ICD-9-CM code for opioid abuse. Using the same methodology as above, the total average per-patient direct health care payer cost for Group A was \$18,388 compared with \$2,210 for matched controls ($P < 0.01$). For Group B, the total average per-patient direct health care cost was \$16,204 compared with \$2,179 for matched controls ($P < 0.01$). In both instances, the direct health care costs of Groups A and B were approximately 8 times as high as the matched controls, consistent with the findings above for the broader group used for this study. It appears that Group A has costs that are higher than Group B, indicating that those patients diagnosed as opioid "abusers" have higher costs than those diagnosed as opioid "dependent." This finding should be interpreted with caution given the different uses of the term opioid abuse. Thus, the range of cost estimates for our sample

of opioid abusers based on alternative groupings of ICD-9-CM codes is \$15,884 to \$18,388, and \$1,830 to \$2,210 for our matched sample.

The descriptive analyses reported above do not control for comorbidities. The methodology adopted here considers direct health care costs for opioid abusers arising from the presence of other comorbid conditions such as pancreatitis, hepatitis, etc., in addition to opioid abuse-related costs. Analysis using a multivariate regression approach (described below) would allow for a more direct comparison of costs between opioid abusers and a matched control while simultaneously controlling for a variety of factors such as comorbidity profiles and demographics that may drive costs. Furthermore, it would be useful to have an alternative benchmark control group with which to compare the costs of opioid abuse; for this purpose, we have chosen a control group of patients with a diagnosis of depression (ICD-9-CM codes 296.2, 296.3, 300.4, 309.0, 309.1, and 311).

Depression is a mental health illness that is common and is diagnosed on a relatively consistent basis. Similar to opioid abuse, this condition is managed by primary care doctors and specialists and is also a costly condition of interest to payers.¹⁵ This regression allows us to compare the costs of an opioid abuser to those of a depressed patient, holding other factors constant, such as age, gender, and the presence of other comorbid conditions. This allows for a more direct and meaningful comparison of the costs associated with opioid abuse.

We constructed a multivariate regression to account for this, where the left-hand variable was the per-patient costs during the 12-month period encompassing the 6 months preindex and

6 months postindex date. Patients were matched on a 3:1 basis (as before), and overlap between the 2 groups was controlled for (e.g., patients who had a diagnosis of both depression and opioid abuse). The regression specification is as below:

$$\text{cost} = \alpha + \beta_1 \text{age} + \beta_2 \text{age}^2 + \beta_3 \text{female} + \sum_{i=1}^3 \gamma_i r_i + \beta_4 \text{abuser} + \beta_5 \text{abuser} \times \text{depressed} + \sum_{j=6}^N \beta_j \text{comorbid}_j + \sum_{k=6}^N \chi_k \text{comorbid}_k \times \text{abuser} + \varepsilon,$$

where *female* is a dummy variable taking the value 1 if the patient is female, 0 otherwise; r_i is a dummy variable taking the value 1 if the patient is in region i , 0 otherwise; *abuser* is a dummy variable taking the value 1 if the patient is an opioid abuser, 0 otherwise; *abuser* $\times$ *depressed* is an interaction term taking the value of 1 if the patient has at least 1 diagnosis for opioid abuse and at least 1 diagnosis for depression, 0 otherwise; and *comorbid_j* are dummy variables taking the value 1 if the patient has a given comorbid condition, 0 otherwise. The variables *comorbid_k* $\times$ *abuser* are interaction terms, taking the value 1 if the patient is an opioid abuser and has a given comorbid condition; ε is the error term.

When we calculated descriptive statistics for our 2 samples, we found that the per-patient costs of opioid abuse were 3.4 times higher than the matched control of depressed patients, \$16,722 for opioid abusers compared with \$4,875 for depressed patients. Based on the regression results that control for the effects of comorbid conditions, we found that the incremental costs of opioid abuse relative to depressed patients was \$3,040, indicating that opioid abusers were 1.8 times as costly as depressed patients (\$3,040 vs. \$3,619) (Table 5). The coefficient estimates on the comorbidities included in the regression indicated that the incremental costs of the comorbidities (i.e., the additional costs compared with patients without the comorbid condition) of other substance abuse, psychiatric diagnoses, and trauma, were \$5,169, \$2,677, and \$3,145, respectively. The results suggested that patients who were abusers and had a psychiatric diagnosis or a trauma incident had additional psychiatric or trauma costs of \$2,025 and \$2,066, respectively. That is, psychiatric costs were \$4,702 (i.e., \$2,677 + \$2,025) and \$5,211 (i.e., \$3,145 + \$2,066) for opioid abusers compared with those without that comorbid condition.

Discussion

The analyses presented here highlight the substantial payer burden associated with patients who are diagnosed as opioid abusers. We are not aware of any other studies that have systematically quantified and compared the direct medical and drug costs of opioid abusers with a cohort of nonabusers. This group of opioid abusers has direct health care costs that are more than 8 times higher than those of nonabusers. These cost measures were the total per-patient direct health care costs and included costs associated with other comorbid conditions. Even

when one controls for comorbidities using a multivariate regression analysis, we found that opioid abusers were 1.8 times as costly to the payer as a matched control of depressed patients. In fact, much of the cost of opioid abuse is driven by such things as hospitalizations and emergency room visits. This analysis has shown that opioid abusers have higher prevalence rates of certain comorbidities (such as nonopioid poisoning, hepatitis [A, B, C], pancreatitis, etc.) and have higher utilization rates of medical services such as hospital inpatient visits. This suggests that these factors may have jointly contributed to the higher level of per-patient costs associated with opioid abusers compared with nonabusers.

Limitations

Focusing only on the direct health care costs understates the full cost burden imposed by indirect costs associated with disability, absenteeism, and presenteeism (defined as the feeling that one must go to work even if one is too ill to be productive or effective). It is important for payers to consider indirect costs in calculating the true overall burden of opioid abuse. Birnbaum et al. note that lost productivity costs accounted for 50% of the societal cost of prescription opioid abuse in the United States in 2001.¹²

Since the diagnosis codes in medical claims do not distinguish between prescription and nonprescription opioid abuse, it was not possible in this study to examine the relationship of nonmedical use of nonprescription (e.g., heroin, cocaine, etc.) drugs to prescription opioid (e.g., morphine, hydrocodone, etc.) and total direct health care costs. Since 58% of opioid abusers had claims for SAOs, LAOs, or both, 42% of opioid abusers (as defined here) may be abusing other prescription drugs or nonprescription (illicit) narcotics. Further research should seek to distinguish between abuse of prescription narcotics and illicit narcotics and measure indirect costs as well as direct costs for prescription and illicit opioids.

A more thorough analysis of the comorbidity profile of opioid abuse patients, including an assessment of the temporal pattern of such comorbidities, would be valuable in understanding cost drivers. For example, if the onset of opioid abuse is associated with human immunodeficiency virus (HIV) or hepatitis (A, B, or C), then a cost offset may be realized by advocating better treatment of opioid abuse; however, longitudinal examinations of temporal patterns may not be possible in administrative claims databases due to relatively limited duration of membership of opioid abusers.

Future research with Medicaid data is also necessary to shed light on the prevalence and costs of opioid abuse among a Medicaid population and possibly to help understand more clearly the causal relationship between opioid abuse and the comorbidities discussed here. The costs of such patients in a Medicaid population could be quite different compared with those reported here from commercial health plan members. It would also be useful to extend the multivariate regression

FIGURE 2 Average Annual Direct Costs* of Opioid Abusers and Nonabusers, 1998-2002

* Costs are in 2003 dollars. The differences between all mean annual costs of opioid abusers and nonabusers are statistically significantly different at the 1% level ($P < 0.01$) except for "Other Costs" for which the "Other Place of Service" component is significantly different at the 5% level ($P < 0.05$).

† "Other Costs" include: "Other Place of Service" and "Emergency Room" costs.

TABLE 5 Regression Results

	Parameter Estimate	Standard Error	P Value
Intercept	3,619	2,258	0.1090
Demographics			
Age	-188	121	0.1213
Age squared	4	2	0.0121
Gender (female = 1)	568	582	0.3293
Regions (reference = Region 4 - West)			
Region 1 - Northeast	75	1,021	0.9411
Region 2 - Midwest	-459	1,098	0.6760
Region 3 - South	-1,421	889	0.1099
Comorbidities (reference = none)			
Other substance abuse	5,169	1,333	0.0001
Psychiatric diagnoses	2,677	664	<0.0001
Trauma	3,145	743	<0.0001
Interaction terms for comorbidities			
Other substance abuse x abuser	1	1,752	0.9996
Psychiatric diagnoses x abuser	2,025	1,371	0.1397
Trauma x abuser	2,066	1,408	0.1425
Abuser (reference = depressed patient)	3,040	1,217	0.0125
Abuser x depressed patient	6,452	1,213	<0.0001

Adjusted r -squared = 0.1612.

Number of observations = 2,880.

Dependent variable = direct health care costs.

analysis to account for additional factors that may drive costs, including duration of abuse, prior medical history, and the presence of multiple substance abuse treatments.

As was noted earlier, the concept of opioid abuse is often interpreted differently by different people. Given the possibility for miscoding with ICD-9-CM codes,¹⁶ we attempted to include all ICD-9-CM codes that related to opioid abuse, recognizing the possibility that those codes may not always capture the phenomenon of opioid abuse.

Conclusion

Opioid abuse is a costly condition that imposes a large direct cost burden on private payers. Opioid abusers have direct health care costs that are approximately 8 times higher than those of nonabusers. These costs are likely driven by higher prevalence rates of costly comorbidities.

Acknowledgments

The authors gratefully acknowledge helpful comments and insights on this paper from Vanja Sikirica, PharmD, manager, primary care outcomes research, and Dilesh Doshi, PharmD, associate director, regional outcomes research, Janssen Medical Affairs, L.L.C., Raritan, NJ, and San Diego, CA, respectively.

Disclosures

Funding for this research was provided by an unrestricted grant from Janssen Medical Affairs, L.L.C. and was obtained by authors Susan Vallow and Jeff Schein, who are employed by Janssen Medical Affairs, L.L.C. Nathaniel Katz is a consultant to Janssen and numerous other pharmaceutical companies that manufacture branded opioid products and nonopioid analgesics; authors Alan G. White, Howard G. Birnbaum, Milena N. Mareva, and Maham Daher disclose no potential bias or conflict of interest relating to this article.

White served as principal author of the study. Study concept and design were contributed primarily by White, Vallow, Schein, and Katz. Analysis and interpretation of data were contributed by all authors. Drafting of the manuscript was primarily the work of White, and its critical revision was the work of White and Vallow. Statistical expertise was contributed by White, Birnbaum, and Daher, and administrative, technical, and/or material support was provided by Analysis Group, Inc., Boston, MA.

References

- Virag T, Packer LE, Davis TR, et al. 1998 National Household Survey on Drug Abuse: Summary Tables. Prevalence Estimates, Standard Errors, and P Values. Vols. 1 & 2. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; August 1999. Available at: <http://www.oas.samhsa.gov/NHSDA/98DetailedTables/sumtab98.pdf>. Accessed May 12, 2004.
- Chromy JR, Davis TR, Emrich SL, et al. 2000 National Household Survey on Drug Abuse: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; March 2002. Available at: <http://www.oas.samhsa.gov/NHSDA/2kdetailedtabs/pdf/2kNHSDAtables-pdf.htm>. Accessed May 12, 2004.
- Barnett K, Bowman KR, Brown JM, et al. Results from the 2001 National Household Survey on Drug Abuse: Volume III: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; September 2002. Available at: http://www.oas.samhsa.gov/nhsda/2k1nhsda/vol3/frontMatter_W.pdf. Accessed May 12, 2004.
- Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration. Office of Applied Studies; September 2004. NSDUH Series H-24, DHHS Publication no. SMA 04-3963.

APPENDIX A ICD-9-CM Diagnosis Codes Associated With Comorbid Conditions

Diagnosis Type	ICD-9-CM Codes	Diagnosis Description	Diagnosis Type	ICD-9-CM Codes	Diagnosis Description
Other substance abuse (excluding opioid 304.0, sedative abuse 304.7 and 305.5)	303.XX	Alcohol dependence syndrome	Hepatitis (alcoholic)	070.41	Acute or unspecified hepatitis C with hepatic coma
	304.1X	Barbiturate and similarly acting or hypnotic dependence		070.42	Hepatitis delta without mention of active hepatitis B disease with hepatic coma
	304.2X	Cocaine dependence	Hepatitis (E and other)	070.44	Chronic hepatitis C with hepatic coma
	304.3X	Cannabis dependence		070.51	Acute or unspecified hepatitis C without mention of hepatic coma
	304.4X	Amphetamine and other psychostimulant dependence	Hepatitis (E and other)	070.52	Hepatitis delta without mention of active hepatitis B disease or hepatic coma
	304.5X	Hallucinogen dependence		070.54	Chronic hepatitis C without mention of hepatic coma
	304.6X	Other specific drug dependence	Hepatitis (E and other)	V02.61	Hepatitis B carrier
	304.8X	Combinations of drug dependence excluding opioid		V02.62	Hepatitis C carrier
	304.9X	Unspecified drug dependence	Hepatitis (E and other)	070.6	Unspecified viral hepatitis with hepatic coma
	305.0X	Alcohol abuse		070.9	Unspecified viral hepatitis without mention of hepatic coma
	305.1X	Tobacco dependence	Hepatitis (E and other)	V02.60	Viral hepatitis
	305.2X	Cannabis abuse		V02.69	Other viral hepatitis carrier
	305.3X	Hallucinogen abuse	Pancreatitis	577.XX	Diseases of the pancreas
	305.4X	Barbiturate and similarly acting sedative or hypnotic abuse		090.XX-099.XX	Syphilis and other venereal diseases
	305.6X	Cocaine abuse	Sexually transmitted diseases	112.1X	Candidiasis of vulva and vagina
	305.7X	Amphetamine and other psychostimulant abuse		112.2X	Candidiasis of other urogenital sites
	305.8X	Antidepressant type abuse	Sexually transmitted diseases	483.1X	Chlamydia
	305.9X	Other, mixed, or unspecified drug abuse		078.19	Other genital warts
	V11.3	Personal history of alcoholism	Sexually transmitted diseases	078.11	Genital warts: condyloma acuminatum
Psychiatric diagnoses	290.XX-302.XX	Psychoses, neurotic disorders & personality disorders, and other nonpsychotic mental conditions		V02.7	Personal history of gonorrhea
	306.XX-319.XX	Neurotic and personality disorders, and other nonpsychotic mental conditions, mental retardation	Sexually transmitted diseases	V02.8	Personal history of other venereal diseases
HIV/AIDS	V11.X (excluding V11.3)	Personal history of mental disorder		647.0	Syphilis
	042.XX	HIV disease	Sexually transmitted diseases	647.1	Gonorrhea carried by the mother during pregnancy
Endocarditis	79.53	HIV virus type 2		647.2	Other venereal diseases carried by the mother during pregnancy
	V08.X	Asymptomatic HIV infection status	Sexually transmitted diseases	614-616	Inflammatory diseases of the female pelvic organs
Endocarditis	795.71	Nonspecific serologic evidence of HIV		131.00	Urogenital trichomoniasis, unspecified
	421.XX	Acute and subacute endocarditis	Sexually transmitted diseases	131.01	Trichomonal vulvovaginitis
Endocarditis	424.9X	Endocarditis, valve unspecified		131.02	Trichomonal urethritis
	424.9X	Endocarditis, valve unspecified, unspecified cause	Sexually transmitted diseases	131.03	Trichomonal prostatitis
Endocarditis	424.91	Endocarditis in diseases classified elsewhere		131.09	Other trichomoniasis
	424.99	Other—any condition classifiable to 424.90 with specified cause, except rheumatic	Sexually transmitted diseases	622.1X	Dysplasia of cervix
Endocarditis	391.1X	Acute rheumatic endocarditis		623.0X	Dysplasia of vagina
	036.42	Meningococcal endocarditis	Herpes simplex	054	Herpes simplex
Endocarditis	074.22	Coxsackie endocarditis		940.XX-949.XX	Burns
	093.2X	Syphilitic endocarditis	Trauma (excluding motor vehicle traffic accidents)	800-829	Fractures
Endocarditis	098.84	Gonococcal endocarditis		830-839	Dislocation
	112.81	Candidal endocarditis	Trauma (excluding motor vehicle traffic accidents)	840-848	Sprains and strains of joints and adjacent muscles
Skin infections /abscesses	680-686	Infections of skin and subcutaneous tissue		850-854	Intracranial injury, excluding those with skull fracture
	681.XX	Cellulitis and abscess of finger and toe	Trauma (excluding motor vehicle traffic accidents)	860-869	Internal injury of thorax, abdomen, and pelvis
Skin infections /abscesses	693.XX	Due to drugs and medicines		870-879	Open wound of head, neck, and trunk
	693.8X	Due to other specified substances taken internally	Trauma (excluding motor vehicle traffic accidents)	880-887	Open wound of upper limb
Skin infections /abscesses	693.9X	Due to unspecified substance taken internally		890-897	Open wound of lower limb
	111.8X	Other specified dermatomycoses	Trauma (excluding motor vehicle traffic accidents)	900-904	Injury to blood vessels
Skin infections /abscesses	111.9X	Dermatomycosis, unspecified		905-909	Late effects of injuries, poisonings, toxic effects, and other external causes
	707.9X	Chronic ulcer of unspecified site	Trauma (excluding motor vehicle traffic accidents)	910-919	Superficial injury
GI bleeding	578.XX	Gastrointestinal hemorrhage		920-924	Contusion with intact skin surface
	456.XX	Esophageal varices with bleeding	Trauma (excluding motor vehicle traffic accidents)	925-929	Crushing injury
GI bleeding	530.8X	Other specified disorders of esophagus		930-939	Effects of foreign body entering through orifice
	531.XX	Gastric ulcer—acute with hemorrhage	Trauma (excluding motor vehicle traffic accidents)	950-957	Injury to nerves and spinal cord
GI bleeding	531.2X	Gastric ulcer—acute with hemorrhage and perforation		958-959	Certain traumatic complications and unspecified injuries
	532.XX	Duodenal ulcer—acute with hemorrhage	Poisoning (excluding opioid abuse: 965.00, 965.02 and 965.09)	960.XX-979.XX	Poisoning by drugs, medicinal and biologic substances
GI bleeding	532.2X	Duodenal ulcer—acute with hemorrhage and perforation		980.XX-989.XX	Toxic effects of substances chiefly nonmedicinal as to source
	533.XX	Peptic ulcer—acute with hemorrhage	Poisoning (excluding opioid abuse: 965.00, 965.02 and 965.09)	960.XX-979.XX	Poisoning by drugs, medicinal and biologic substances
	533.2X	Peptic ulcer—acute with hemorrhage and perforation		980.XX-989.XX	Toxic effects of substances chiefly nonmedicinal as to source
Cirrhosis/chronic or acute liver disease	534.XX	Gastrojejunal ulcer—acute with hemorrhage	Motor vehicle traffic accidents	E810-E819	
	534.2X	Gastrojejunal ulcer—acute with hemorrhage and perforation			
Cirrhosis/chronic or acute liver disease	570.XX	Acute and subacute necrosis of liver	Poisoning (excluding opioid abuse: 965.00, 965.02 and 965.09)	960.XX-979.XX	Poisoning by drugs, medicinal and biologic substances
	571.XX (excluding 571.1)	Chronic liver disease and cirrhosis		980.XX-989.XX	Toxic effects of substances chiefly nonmedicinal as to source
Cirrhosis/chronic or acute liver disease	572.XX	Liver abscess and sequelae of chronic liver disease	Motor vehicle traffic accidents	E810-E819	
	573.XX	Other disorders of liver			
Hepatitis (A,B,C)	070.0	Viral hepatitis A with hepatic coma	Poisoning (excluding opioid abuse: 965.00, 965.02 and 965.09)	960.XX-979.XX	Poisoning by drugs, medicinal and biologic substances
	070.1	Viral hepatitis A without mention of hepatic coma		980.XX-989.XX	Toxic effects of substances chiefly nonmedicinal as to source
Hepatitis (A,B,C)	070.2X	Viral hepatitis B with hepatic coma	Motor vehicle traffic accidents	E810-E819	
	070.3X	Viral hepatitis B without mention of hepatic coma			

APPENDIX A ICD-9-CM Diagnosis Codes Associated With Comorbid Conditions

Diagnosis Type	ICD-9-CM Codes	Diagnosis Description	Diagnosis Type	ICD-9-CM Codes	Diagnosis Description
Other substance abuse (excluding opioid 304.0, sedative abuse 304.7 and 305.5)	303.XX	Alcohol dependence syndrome		070.41	Acute or unspecified hepatitis C with hepatic coma
	304.1X	Barbiturate and similarly acting or hypnotic dependence		070.42	Hepatitis delta without mention of active hepatitis B disease with hepatic coma
	304.2X	Cocaine dependence		070.44	Chronic hepatitis C with hepatic coma
	304.3X	Cannabis dependence		070.51	Acute or unspecified hepatitis C without mention of hepatic coma
	304.4X	Amphetamine and other psychostimulant dependence		070.52	Hepatitis delta without mention of active hepatitis B disease or hepatic coma
	304.5X	Hallucinogen dependence		070.54	Chronic hepatitis C without mention of hepatic coma
	304.6X	Other specific drug dependence		V02.61	Hepatitis B carrier
	304.8X	Combinations of drug dependence excluding opioid		V02.62	Hepatitis C carrier
	304.9X	Unspecified drug dependence	Hepatitis (alcoholic)	571.1	Acute alcoholic hepatitis
	305.0X	Alcohol abuse			
	305.1X	Tobacco dependence	Hepatitis (E and other)	070.43	Hepatitis E with hepatic coma
	305.2X	Cannabis abuse		070.49	Other specified viral hepatitis with hepatic coma
	305.3X	Hallucinogen abuse		070.53	Hepatitis E without mention of hepatic coma
	305.4X	Barbiturate and similarly acting sedative or hypnotic abuse		070.59	Other specified viral hepatitis without mention of hepatic coma
	305.6X	Cocaine abuse		070.6	Unspecified viral hepatitis with hepatic coma
	305.7X	Amphetamine and other psychostimulant abuse		070.9	Unspecified viral hepatitis without mention of hepatic coma
	305.8X	Antidepressant type abuse		V02.60	Viral hepatitis
	305.9X	Other, mixed, or unspecified drug abuse		V02.69	Other viral hepatitis carrier
	V11.3	Personal history of alcoholism			
Psychiatric diagnoses	290.XX-302.XX	Psychoses, neurotic disorders & personality disorders, and other nonpsychotic mental conditions	Pancreatitis	577.XX	Diseases of the pancreas
	306.XX-319.XX	Neurotic and personality disorders, and other nonpsychotic mental conditions, mental retardation			
	V11.X (excluding V11.3)	Personal history of mental disorder	Sexually transmitted diseases	090.XX-099.XX	Syphilis and other venereal diseases
HIV/AIDS	042.XX	HIV disease		112.1X	Candidiasis of vulva and vagina
	79.53	HIV virus type 2		112.2X	Candidiasis of other urogenital sites
	V08.X	Asymptomatic HIV infection status		483.1X	Chlamydia
	795.71	Nonspecific serologic evidence of HIV		078.19	Other genital warts
Endocarditis	421.XX	Acute and subacute endocarditis		078.11	Genital warts: condyloma acuminatum
	424.9X	Endocarditis, valve unspecified		V02.7	Personal history of gonorrhea
	424.9X	Endocarditis, valve unspecified, unspecified cause		V02.8	Personal history of other venereal diseases
	424.91	Endocarditis in diseases classified elsewhere		647.0	Syphilis
	424.99	Other—any condition classifiable to 424.90 with specified cause, except rheumatic		647.1	Gonorrhea carried by the mother during pregnancy
	391.1X	Acute rheumatic endocarditis		647.2	Other venereal diseases carried by the mother during pregnancy
	036.42	Meningococcal endocarditis		614-616	Inflammatory diseases of the female pelvic organs
	074.22	Coxsackie endocarditis		131.00	Urogenital trichomoniasis, unspecified
	093.2X	Syphilitic endocarditis		131.01	Trichomonal vulvovaginitis
	098.84	Gonococcal endocarditis		131.02	Trichomonal urethritis
	112.81	Candidal endocarditis		131.03	Trichomonal prostatitis
Skin infections /abscesses	680-686	Infections of skin and subcutaneous tissue		131.09	Other trichomoniasis
	681.XX	Cellulitis and abscess of finger and toe		622.1X	Dysplasia of cervix
	693.XX	Due to drugs and medicines		623.0X	Dysplasia of vagina
	693.8X	Due to other specified substances taken internally	Herpes simplex	054	Herpes simplex
	693.9X	Due to unspecified substance taken internally	Burns	940.XX-949.XX	
	111.8X	Other specified dermatomycoses	Trauma (excluding motor vehicle traffic accidents)	800-829	Fractures
	111.9X	Dermatomycosis, unspecified		830-839	Dislocation
GI bleeding	707.9X	Chronic ulcer of unspecified site		840-848	Sprains and strains of joints and adjacent muscles
	578.XX	Gastrointestinal hemorrhage		850-854	Intracranial injury, excluding those with skull fracture
	456.XX	Esophageal varices with bleeding		860-869	Internal injury of thorax, abdomen, and pelvis
	530.8X	Other specified disorders of esophagus		870-879	Open wound of head, neck, and trunk
	531.XX	Gastric ulcer—acute with hemorrhage		880-887	Open wound of upper limb
	531.2X	Gastric ulcer—acute with hemorrhage and perforation		890-897	Open wound of lower limb
	532.XX	Duodenal ulcer—acute with hemorrhage		900-904	Injury to blood vessels
	532.2X	Duodenal ulcer—acute with hemorrhage and perforation		905-909	Late effects of injuries, poisonings, toxic effects, and other external causes
	533.XX	Peptic ulcer—acute with hemorrhage		910-919	Superficial injury
	533.2X	Peptic ulcer—acute with hemorrhage and perforation		920-924	Contusion with intact skin surface
Cirrhosis/chronic or acute liver disease	570.XX	Acute and subacute necrosis of liver		925-929	Crushing injury
	571.XX (excluding 571.1)	Chronic liver disease and cirrhosis		930-939	Effects of foreign body entering through orifice
	572.XX	Liver abscess and sequelae of chronic liver disease		950-957	Injury to nerves and spinal cord
	573.XX	Other disorders of liver		958-959	Certain traumatic complications and unspecified injuries
Hepatitis (A,B,C)	070.0	Viral hepatitis A with hepatic coma	Motor vehicle traffic accidents	E810-E819	
	070.1	Viral hepatitis A without mention of hepatic coma	Poisoning (excluding opioid abuse: 965.00, 965.02 and 965.09)	960.XX-979.XX	Poisoning by drugs, medicinal and biologic substances
	070.2X	Viral hepatitis B with hepatic coma		980.XX-989.XX	Toxic effects of substances chiefly nonmedicinal as to source
	070.3X	Viral hepatitis B without mention of hepatic coma			

APPENDIX B Average Annual Direct Costs of Opioid Abusers and Nonabusers (1998-2002)
(Patients Aged 12-64 Years) (2003 Dollars)

	Opioid Abusers (N = 712)						Nonabusers (N = 2,136)						Cost Difference*	Mean Opioid Abuser Costs to Nonabuser Costs†
	Average Annual Cost per Patient						Average Annual Cost per Patient							
	Mean‡	% of Total Direct Cost	SD	25th P	Median	75th P	Mean‡	% of Total Direct Cost	SD	25th P	Median	75th P		
Drug cost	\$2,034 ^a	13%	\$3,693	\$121	\$769	\$2,291	\$386 ^a	21%	\$1,166	\$0	\$28	\$303	\$1,648 ^a	5.3 ^a
Medical cost	\$13,850 ^a	87%	\$21,392	\$2,508	\$7,562	\$15,602	\$1,444 ^a	79%	\$6,861	\$0	\$198	\$900	\$12,406 ^a	9.6 ^a
Doctor's visit/outpatient	5,000 ^a	31%	7,406	859	2,699	6,501	906 ^a	50%	2,900	0	157	738	4,094 ^a	5.5 ^a
Mental health outpatient	398 ^a	3%	1,047	0	0	351	22 ^a	1%	178	0	0	0	376 ^a	17.8 ^a
Hospital inpatient	7,239 ^a	46%	16,763	0	1,800	7,396	310 ^a	17%	2,064	0	0	0	6,928 ^a	23.3 ^a
Emergency room	136 ^a	1%	702	0	0	0	13 ^a	1%	111	0	0	0	123 ^a	10.1 ^a
Mental health inpatient	420 ^a	3%	1,563	0	0	0	8 ^a	0%	187	0	0	0	413 ^a	55.9 ^a
Other place of service	657 ^b	4%	3,939	0	48	322	185 ^b	10%	5,429	0	0	12	472 ^b	3.6 ^b
Total direct cost	\$15,884 ^a	—	\$22,371	\$3,691	\$9,138	\$18,226	\$1,830 ^a	-	\$7,208	\$1	\$339	\$1,516	\$14,054 ^a	8.7 ^a
Motor vehicle traffic accidents	6 ^b	—	65	0	0	0	1 ^b	-	14	0	0	0	6 ^b	11.1 ^b
Trauma	409 ^a	—	1,519	0	0	153	87 ^a	-	526	0	0	0	322 ^a	4.7 ^a
Substance abuse treatment inpatient	879 ^a	—	3,972	0	0	0	8 ^a	-	175	0	0	0	871 ^a	112.7 ^a
Substance abuse treatment outpatient	255 ^a	—	1,387	0	0	0	2 ^a	-	36	0	0	0	253 ^a	139.6 ^a
Burns	13	—	262	0	0	0	0	-	5	0	0	0	13	59.9

* The cost difference represents the excess costs of opioid abusers, i.e., the difference between the average annual per patient direct costs of opioid abusers and those of nonabusers.

† The ratio of the costs of opioid abusers to those of nonabusers.

‡ t tests were conducted to compare the mean annual costs of opioid abusers and nonabusers. ^a denotes significance at the 1% level ($P < 0.01$) and ^b denotes significance at the 5% level ($P < 0.05$).

Authors

ALAN G. WHITE, PhD, is a vice president, HOWARD G. BIRNBAUM, PhD, is a vice president, MILENA N. MAREVA, BA, is a senior analyst, and MAHAM DAHER, BA, is a senior analyst, Analysis Group, Inc., Boston, Massachusetts; SUSAN VALLOW, RPh, MBA, MA, is associate director, primary care outcomes research, and JEFF SCHEIN, DrPH, MPH, is senior director, primary care outcomes research, Janssen Medical Affairs, L.L.C., Raritan, New Jersey; NATHANIEL KATZ, MD, is a vice president, medical affairs and pain research, Inflexxion, Inc., Newton, Massachusetts.

AUTHOR CORRESPONDENCE: Alan G. White, PhD, Vice President, Analysis Group, Inc., 111 Huntington Ave., 10th Fl., Boston, MA 02199.

Tel: (617) 425-8217; Fax: (617) 425-8001; E-mail: awhite@analysisgroup.com

Copyright© 2005, Academy of Managed Care Pharmacy. All rights reserved.